We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: venous thromboembolism
MedXY News
EnglishTag

venous thromboembolism

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Combined Oral Contraception: Evolution, Safety, and Clinical Implications
Clinical Updatesnatural estrogenvenous thromboembolism

Combined Oral Contraception: Evolution, Safety, and Clinical Implications

By MedXY|Sep 7, 2026

This review examines the development, efficacy, and safety of combined oral contraceptives (COCs), highlighting the emergence of natural-estrogen-containing formulations and their role in optimizing contraceptive care.

High Venous Thromboembolism Incidence in Endometrial Cancer Patients Undergoing Chemotherapy: Implications for Risk Stratification and Prophylaxis
newschemotherapyvenous thromboembolism
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

High Venous Thromboembolism Incidence in Endometrial Cancer Patients Undergoing Chemotherapy: Implications for Risk Stratification and Prophylaxis

By MedXY|Sep 1, 2026

Over 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project
Hematology-Oncology質改善venous thromboembolism

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project

By MedXY|Aug 25, 2026

A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.

Endometriosis Linked to Elevated Long-Term Risk of Venous Thromboembolism: Insights from a Nationwide Danish Cohort Study
Hematology-Oncologyendometriosisvenous thromboembolism

Endometriosis Linked to Elevated Long-Term Risk of Venous Thromboembolism: Insights from a Nationwide Danish Cohort Study

By MedXY|Aug 22, 2026

A comprehensive Danish nationwide study reveals that women with endometriosis face a significantly increased long-term risk of venous thromboembolism, underscoring the need for heightened clinical vigilance and tailored risk management.

Preventing Maternal Deaths from Venous Thromboembolism: Insights from a 12-Year Nationwide French Analysis
Hematology-Oncologyvenous thromboembolismthromboprophylaxis

Preventing Maternal Deaths from Venous Thromboembolism: Insights from a 12-Year Nationwide French Analysis

By MedXY|Aug 19, 2026

A nationwide French study reveals that nearly half of maternal deaths due to venous thromboembolism are preventable, emphasizing the importance of ongoing risk assessment and appropriate thromboprophylaxis during pregnancy and postpartum.

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial
Hematology-Oncologyisolated distal DVTRecurrence Risk

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

By MedXY|Jul 7, 2026

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Pregnancy in Women With Vascular Malformations Carries High Risks of Postpartum Hemorrhage and Symptom Worsening, While Thromboembolism Clusters in Extensive Lower-Extremity Disease
newsPregnancyvascular malformations

Pregnancy in Women With Vascular Malformations Carries High Risks of Postpartum Hemorrhage and Symptom Worsening, While Thromboembolism Clusters in Extensive Lower-Extremity Disease

By MedXY|Aug 18, 2026

A nationwide Dutch study suggests pregnancy in women with peripheral vascular malformations is frequently complicated by symptom progression and postpartum hemorrhage, with venous thromboembolism concentrated in extensive lower-extremity ma

Bempedoic Acid Was Linked to Fewer Venous Thromboembolic Events in Statin-Intolerant Patients in CLEAR Outcomes
Cardiologybempedoic acidCLEAR Outcomes

Bempedoic Acid Was Linked to Fewer Venous Thromboembolic Events in Statin-Intolerant Patients in CLEAR Outcomes

By MedXY|Jun 3, 2026

In a post hoc analysis of CLEAR Outcomes, bempedoic acid was associated with a significantly lower risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, among statin-intolerant patients at high cardiovascula

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome
Diabetes & EndocrinologyACTH-dependent Cushing syndromeRivaroxaban

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome

By MedXY|May 26, 2026

Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.

Blocking P2Y14R Emerges to Combat Venous Thromboembolism via Neutrophil-Plaque Interaction
CardiologyP2Y14RProglumide

Blocking P2Y14R Emerges to Combat Venous Thromboembolism via Neutrophil-Plaque Interaction

By MedXY|Apr 24, 2026

New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients
Cardiologybiomarkersbleeding

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients

By MedXY|Apr 22, 2026

Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization
CardiologybiomarkersMendelian Randomization

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization

By MedXY|Apr 2, 2026

This review synthesizes findings from a landmark proteomic study identifying 23 plasma proteins associated with VTE risk, highlighting novel pathways in immunity and vascular senescence while exploring causal links through Mendelian Randomi

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk
Cardiologybiomarkerscardiovascular disease

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

By MedXY|Mar 28, 2026

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference
Cardiologybiomarkerscardiovascular risk

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

By MedXY|Mar 18, 2026

This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses
CardiologybiomarkersMendelian Randomization

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses

By MedXY|Mar 2, 2026

A groundbreaking large-scale proteomic study identified 15 novel plasma markers for venous thromboembolism, highlighting biological pathways in extracellular matrix regulation and vascular senescence.

Age-Adjusted D-Dimer Cutoffs Safely Rule Out Deep Vein Thrombosis: Results from the ADJUST-DVT Trial
Emergency MedicineClinical DiagnosticsD-dimer

Age-Adjusted D-Dimer Cutoffs Safely Rule Out Deep Vein Thrombosis: Results from the ADJUST-DVT Trial

By MedXY|Jan 6, 2026

The ADJUST-DVT study confirms that an age-adjusted D-dimer cutoff (age × 10 µg/L) safely increases the number of patients in whom deep vein thrombosis can be ruled out without imaging, particularly benefiting patients over 75 years of age.

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men
Cardiologycardiovascular riskgender-affirming hormone therapy

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men

By MedXY|Nov 28, 2025

A large Dutch cohort study found that after adjusting for socioeconomic status and lifestyle, transgender women on oestradiol had lower myocardial infarction (MI) risk but higher venous thromboembolism (VTE) risk; transgender men on testost

Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents
newsCOVID-19 vaccinationmyocarditis

Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents

By MedXY|Nov 24, 2025

A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT1

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
CardiologyExtended TherapyOral Anticoagulation

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

By MedXY|Nov 22, 2025

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha

Continued versus Discontinued Oral Anticoagulant Therapy for Unprovoked Venous Thromboembolism: A Target Trial Emulation and Evidence Synthesis
Cardiologybleedingclinical outcomes

Continued versus Discontinued Oral Anticoagulant Therapy for Unprovoked Venous Thromboembolism: A Target Trial Emulation and Evidence Synthesis

By MedXY|Nov 22, 2025

Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durati

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities